EUVIMEDObjevte EUVIMED
Multizentrische StudieBeobachtungsstudieVergleichsstudie

Drug‐Coated Balloons in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS‐CTO Registry

Deniz Mutlu iD, Athanasios Rempakos iD, Dimitrios Strepkos iD, Pedro E P Carvalho iD, Michaella Alexandrou iD, Eleni Kladou iD, Ozgur Selim Ser iD, Lorenzo Azzalini iD, Farouc A Jaffer, Luiz Ybarra, Omer Goktekin, Mahmut Uluganyan iD and 20 more

Catheterization and Cardiovascular Interventions · 2025-12 · 106 (7) · 3783-3795

DOI: 10.1002/ccd.70240 ↗

At a glance

Multizentrische Studie in Catheterization and Cardiovascular Interventions, 2025-12. Written by Deniz Mutlu and 31 co-authors. Institution: Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA. Major MEDLINE topics: Coronary Occlusion, Coated Materials, Biocompatible, Cardiac Catheters, Angioplasty, Balloon, Coronary. Cited 3 times so far (Crossref); 38 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

There is limited information on the use of drug‐coated balloons (DCBs) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI).

Aims

To assess the frequency and outcomes of DCB use in CTO PCI.

Objective

This study evaluated the frequency and outcomes of DCB use in a large, multicenter CTO PCI registry.

Methods

We analyzed 12,146 patients who underwent 12,157 successful CTO PCIs at 59 centers from 2018 to 2025.

Results

DCBs were used in 454 patients (3.7%) with increasing frequency over time ( p = 0.020). A DCB‐only strategy was used in 48.4% of the patients and a hybrid strategy combining DCBs and drug‐eluting stents (DES) was used in 51.6% of patients. Patients treated with DCB (both strategies) had low prevalence of comorbidities. Compared with the DES cases, DCB only cases had favorable angiographic characteristics, lower mean J‐CTO (Japanese CTO) score (1.83 ± 1.03 vs. 2.27 ± 1.23; p < 0.001), and similar technical success (96.3% vs. 97.3%; p = 0.640), and in‐hospital major adverse cardiac events (MACE). The hybrid and DCB‐only strategies had comparable technical success and in‐hospital MACE. During a median follow‐up of 323 (170–429) days, DCB only cases had lower MACE than the other strategies (hazard ratio [HR] 0.41, 95% CI 0.17–0.96, p = 0.040). After multivariable adjustment, the association remained significant (HR 0.39, 95% CI 0.16–0.92, p = 0.032).

Conclusions

DCBs are increasingly being used in CTO PCI. A DCB only strategy was used in less complex lesions and was associated with similar technical success and in‐hospital MACE compared with hybrid or DES strategies. A DCB only strategy was associated with lower long‐term MACE.

Subjects

MeSH terms (MEDLINE)

Coronary OcclusionCoated Materials, BiocompatibleCardiac CathetersAngioplasty, Balloon, CoronaryHumansRegistriesMaleFemaleTreatment OutcomeAgedChronic DiseaseTime FactorsMiddle AgedRisk FactorsRetrospective StudiesRisk AssessmentDrug-Eluting Stents

Substances

Coated Materials, Biocompatible

Authors and institutions

  • Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
  • Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
  • University of Washington, Seattle, Washington, USA.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Western University, London, Ontario, Canada.
  • Memorial Bahcelievler Hospital, Istanbul, Turkey.

ORCID profiles: Deniz Mutlu, Athanasios Rempakos, Dimitrios Strepkos, Pedro E P Carvalho, Michaella Alexandrou, Eleni Kladou, Ozgur Selim Ser, Lorenzo Azzalini, Mahmut Uluganyan, Olga C Mastrodemos, Sandeep Jalli, Yader Sandoval, Emmanouil S Brilakis, Sevket Gorgulu

Cite

APA

Mutlu, D., Rempakos, A., Strepkos, D., Carvalho, P. E. P., Alexandrou, M., Kladou, E., Ser, O. S., Azzalini, L., Jaffer, F. A., Ybarra, L., Goktekin, O., Uluganyan, M., Ozdemir, R., Elbarouni, B., Alaswad, K., Davies, R., ElGuindy, A., Kocas, C., Sural, S., …, & Gorgulu, S. (2025). Drug‐Coated Balloons in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS‐CTO Registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70240

Vancouver

Mutlu D, Rempakos A, Strepkos D, Carvalho PEP, Alexandrou M, Kladou E, et al. Drug‐Coated Balloons in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS‐CTO Registry. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70240

BibTeX
@article{Mutlu2025,
  author = {Mutlu, Deniz and Rempakos, Athanasios and Strepkos, Dimitrios and Carvalho, Pedro E P and Alexandrou, Michaella and Kladou, Eleni and Ser, Ozgur Selim and Azzalini, Lorenzo and Jaffer, Farouc A and Ybarra, Luiz and Goktekin, Omer and Uluganyan, Mahmut and Ozdemir, Ramazan and Elbarouni, Basem and Alaswad, Khaldoon and Davies, Rhian and ElGuindy, Ahmed and Kocas, Cuneyt and Sural, Sefa and Poommipanit, Paul and Frizzel, Jarrod and Basir, Mir B and Raj, Leah and Young, Laura and Rangan, Bavana V and Mastrodemos, Olga C and Sara, Jaskanwal Deep Singh and Jalli, Sandeep and Sandoval, Yader and Burke, M Nicholas and Brilakis, Emmanouil S and Gorgulu, Sevket},
  title = {Drug‐Coated Balloons in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS‐CTO Registry},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.70240}
}
Start for free →